Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03ROX
|
|||
| Former ID |
DAP000305
|
|||
| Drug Name |
Betaxolol
|
|||
| Synonyms |
Betaxololum; Betazolol; KERLEDEX; Kerlone; Betaxolol HCL; SL 75212; Betaxolol (INN); Betaxolol (TN); Betaxolol [INN:BAN]; Betaxololum [INN-Latin]; Betoptic (TN); Betoptic S (TN); Kerlone (TN); Lokren (TN); SL-75212; ALO-1401-02; (+/-)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; 1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1], [2] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Lorex Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H29NO3
|
|||
| Canonical SMILES |
CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O
|
|||
| InChI |
1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3
|
|||
| InChIKey |
NWIUTZDMDHAVTP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 63659-18-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9067, 4422029, 7978782, 8151588, 11466410, 11467530, 11486220, 14776435, 26751960, 29221537, 46506041, 47285407, 47656606, 47953968, 48328568, 48403963, 48415634, 49698465, 50022975, 50104633, 50655308, 51091849, 57321285, 85208966, 85788861, 90341580, 92308843, 92719119, 92729932, 96099855, 103164936, 103936438, 104171116, 104300392, 124749530, 124879433, 124879434, 124879436, 125329917, 126621071, 126650548, 126670422, 128764229, 131322111, 134337617, 135004759, 135565733, 135649987, 135692415, 137111818
|
|||
| ChEBI ID |
CHEBI:3082
|
|||
| ADReCS Drug ID | BADD_D00263 ; BADD_D00264 ; BADD_D01266 | |||
| SuperDrug ATC ID |
C07AB05; S01ED02
|
|||
| SuperDrug CAS ID |
cas=063659187
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Lactobacillus paracasei
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Lactobacillus paracasei was decreased by Betaxolol hydrochloride (adjusted p-values: 6.48E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-1 (ADRB1) | Target Info | Antagonist | [4], [5] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Gap junction | ||||
| Salivary secretion | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta1 adrenergic receptor signaling pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 549). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29. | |||
| REF 5 | Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br J Pharmacol. 2000 Jun;130(4):759-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.